NCT01358227已完成1 期
A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors
Proacta, Incorporated2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Determine the maximum tolerated dose (MTD) of PR104 when administered weekly
研究概览
简要总结
The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or more
- •Histologically confirmed malignancy for which no effective therapy exists
- •Measurable or evaluable disease
- •ECOG Performance Status of 0 or
- •See Section 15.1 (ECOG performance status) for definition of ECOG Performance Status 0 and 1
- •Ability to read, understand and provide written informed consent
- •If the subject is on systemic steroids, the dose of steroids must be stable for at least two weeks prior to the first dose of PR-104
排除标准
- •Licensed or investigational anti-cancer therapy (including radiotherapy) within four weeks of the baseline disease assessment (within six weeks for nitrosoureas and Mitomycin C). Subjects on androgen deprivation therapy are allowed on study and may continue to receive androgen deprivation therapy while one study
- •Prior radiotherapy to more than 25% of bone marrow; prior high-dose chemotherapy (including either myeloablative or non-myeloablative transplants); or prior receipt of more than three chemotherapy regimens
- •Absolute neutrophil count of < 1.5 x 109/L
- •Platelet count of < 100 x 109/L
- •Hemoglobin level of < 90 g/L (or requiring a red blood cell transfusion to maintain hemoglobin > 90 g/L)
- •Serum bilirubin greater than the upper limit of normal
- •ALT and AST greater than 2.5 times the upper limit of normal
- •Serum creatinine less than 1.5 times upper limit of normal
- •Prothrombin time (PT-INR) or activated partial thromboplastin time (APTT) greater than 1.1 times the upper limit of normal range
- •Women who are pregnant, breast-feeding or planning to become pregnant during the study
- •Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose of study medication. See section 5.11 (Contraceptives) for definition of effective methods of contraception
- •Evidence of any other significant medical disorder or laboratory finding that in the opinion of the Investigator compromises the subject's safety during study participation, including uncontrolled infection or infection requiring a concomitant parenteral antibiotic
- •Plans for concomitant anti-cancer therapy (excluding androgen deprivation therapy) while on study
- •Less than four weeks since major surgery
- •Known to be HIV positive, Hepatitis B sAg positive or Hepatitis C positive with abnormal liver function tests
- •No known contraindication to single doses of naproxen
研究组 & 干预措施
PR104
Experimental
干预措施: PR104 (Drug)
结局指标
主要结局
Determine the maximum tolerated dose (MTD) of PR104 when administered weekly
时间窗: 4 weeks (cycle 1)
MTD is based on cycle 1 data and defined as the maximum dose that can be administered to 6 subjects with no more than one of the following DLTs: * Grade 4 thrombocytopenia * Grade 4 heme toxicity (excluding thrombocytopenia) that lasts for ≥ 5 days (Neutrophils \< 500/mm3, ANC ≤ 0.5 K/mm3, lymphocytes \< 1K/mm3, HGB \< 6.5 gm/dL) * Non-heme toxicity ≥ Grade 3 despite appropriate treatment * Neutropenic fever * Grade 2 or higher neurotoxicity of ≥ 1 week * Any toxicity of Grade 2 or higher that has not resolved within 2 weeks of end of cycle 1 (except grade 2 alopecia)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Attention Deficit Disorders With HyperactivityAttention Deficit Hyperactivity DisordersAttention Deficit Hyperactivity DisorderNCT00334880New River Pharmaceuticals420
撤回
3 期
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)Adult-Onset Still's DiseaseAOSDNCT05432960R-Pharm International, LLC
暂停
1 期
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)NCT02117336Piramal Enterprises Limited36
终止
1 期
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)Select Relapsed/Refractory Lymphoid MalignanciesNCT06761586Aurigene Discovery Technologies Limited9
已完成
1 期
An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced CirrhosisHepatitis C Virus-infected CirrhosisNCT02195440Komagome Hospital14